News
Media
Conferences
Publication
Job Board
CME/CE
Partners
Editorial
Resources
Subscribe

Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Articles|August 23, 2022

Figures for Interest Grows in Treatment of Mood Disorders by Classic Psychedelics

Author(s)Nicole Ledwos, MSc, M. Ishrat Husain, MD (Res), MBBS, MRCPsych, David J. Castle, MB, ChB, MRCPsych, FRANZCP

This is the extra table for "Interest Grows in Treatment of Mood Disorders by Classic Psychedelics."

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

Metabolic Risk, Residual Insomnia, and Seltorexant

ByJane Tiller, MD

June 25th 2026

Seltorexant as Adjunctive Therapy for MDD With Insomnia

Seltorexant as Adjunctive Therapy for MDD With Insomnia

ByJane Tiller, MD

June 24th 2026

depression

Positive Topline Results From Phase 3 Emerge Study of DT120 ODT in Major Depressive Disorder

June 22nd 2026

How Can Sleep Disruption Trigger Mood Episodes?

ByColleen McClung, PhD

June 19th 2026

Psychedelic-Assisted Healing for System-Impacted People: A New Research and Policy Initiative

Psychedelic-Assisted Healing for System-Impacted People: A New Research and Policy Initiative

BySia Henry, JD

June 18th 2026

Latest CME

Southern California Psychiatry Conference

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Trending on Psychiatric Times

Preventing Relapse in Schizophrenia: Focus on Women’s Mental Health

Seltorexant as Adjunctive Therapy for MDD With Insomnia

Psychiatric Comorbidities in Adults With Congenital Heart Disease and the Need for Interdisciplinary Care

Podcast: Practical Insights Into the Evolving Treatment of Bipolar Disorder With David Dunner, MD, FACPsych

Positive Topline Results From Phase 3 Emerge Study of DT120 ODT in Major Depressive Disorder